Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
David Planchard(Université Paris-Saclay), Kunihiko Kobayashi(Saitama International Medical Center), Yuri Rukazenkov(Chinese University of Hong Kong), Jonathan W. Goldman(University of California, Los Angeles), Sang‐We Kim(Ulsan College), Pasi A. Jänne(Harvard University), Sarayut Lucien Geater(Prince of Songkla University), Natalia Valdiviezo(Instituto Nacional de Enfermedades Neoplásicas), James Chih‐Hsin Yang(National Taiwan University Hospital), Ying Cheng(Jilin Province Tumor Hospital), Chee Khoon Lee(The University of Sydney), Dana Ghiorghiu(AstraZeneca (United Kingdom)), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Jean-Marc Maurel(Harbin Medical University), Shunichi Sugawara(Sendai Kousei Hospital), Yun Fan(Zhejiang Cancer Hospital), Yan Yu(Binzhou Medical University), Alex Todd(Harbin Medical University), Igor Andrašina(Harbin Medical University), Samreen Ahmed(University Hospitals of Leicester NHS Trust), Noriko Yanagitani(The Cancer Institute Hospital)
Cited by 695
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k